Overcoming the Cost and Performance Limitations of ELISA with xMAP® Technology
20 November 2015

For nearly half a century, immunoassays have been the primary source for detection of analytes of interest in biological samples for both life science research and clinical diagnostics. While widely utilized, ELISA has limitations, and in the past 15 years, a new technology has emerged that offers the benefits of the ELISA, but also enables the added value of higher throughput, increased flexibility, reduced sample volume, and low cost with the same workflow as ELISA. This application note shows a comparison of a sandwich immunoassay on ELISA and xMAP Technology using the MAGPIX system from Luminex. The assay was built to detect the soluble form of the Tumor Necrosis Factor Receptor 2 (TNF RII).